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Non-steroidal or opioid analgesia use for
children with musculoskeletal injuries (the
No OUCH study): statistical analysis plan
Anna Heath1,2,3* , Maryna Yaskina4, Gareth Hopkin5, Terry P. Klassen6,7, Christopher McCabe5, Martin Offringa1,8,9,
Petros Pechlivanoglou8,9, Juan David Rios1, Naveen Poonai10,11, Samina Ali12,13 and on behalf of the KidsCAN PERC
Innovative Pediatric Clinical Trials No OUCH Study Group
Abstract
Background: Pediatric musculoskeletal injuries cause moderate to severe pain, which should ideally be addressed
upon arrival to the emergency department (ED). Despite extensive research in ED-based pediatric pain treatment,
recent studies confirm that pain management in this setting remains suboptimal. The No OUCH study consist of
two complementary, randomized, placebo-controlled trials that will run simultaneously for patients presenting to
the ED with an acute limb injury and a self-reported pain score of at least 5/10, measured via a verbal numerical
rating scale (vNRS). Caregiver/parent choice will determine whether patients are randomized to the two-arm or
three-arm trial. In the two-arm trial, patients will be randomized to receive either ibuprofen alone or ibuprofen in
combination with acetaminophen. In the three-arm trial, patients can also be randomized to a third arm where
they would receive ibuprofen in combination with hydromorphone. This article details the statistical analysis plan
for the No OUCH study and was submitted before the trial outcomes were available for analysis.
Methods/design: The primary endpoint of the No OUCH study is self-reported pain at 60 min, recorded using a
vNRS. The principal safety outcome is the presence of any adverse event related to study drug administration.
Secondary effectiveness endpoints include pain measurements using the Faces Pain Scale-Revised and the visual
analog scale, time to effective analgesia, requirement of a rescue analgesic, missed fractures, and observed pain
reduction using different definitions of successful analgesia. Secondary safety outcomes include sedation measured
using the Ramsay Sedation Score and serious adverse events. Finally, the No OUCH study investigates the reasons
given by the caregiver for selecting the two-arm (Non-Opioid) or three-arm (Opioid) trial, caregiver satisfaction,
physician preferences for analgesics, and caregiver comfort with at-home pain management.
(Continued on next page)
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Discussion: The No OUCH study will inform the relative effectiveness of acetaminophen and hydromorphone, in
combination with ibuprofen, and ibuprofen alone as analgesic agents for patients presenting to the ED with an
acute musculoskeletal injury. The data from these trials will be analyzed in accordance with this statistical analysis
plan. This will reduce the risk of producing data-driven results and bias in our reported outcomes.
Trial registration: ClinicalTrials.gov NCT03767933. Registered on December 7, 2018.
Keywords: Statistical analysis plan, Musculoskeletal injury, Pain management, Emergency department, Patient
preference, Opioids, Analgesia
Background
Children who visit the emergency department (ED) after a
musculoskeletal (MSK) injury often suffer moderate to se-
vere pain [1, 2]. EDs, particularly the triage area, are usu-
ally the initial point of contact for children with MSK
injuries and are therefore an ideal setting in which to
manage pain by administering analgesia. Despite a sub-
stantial body of research in the area of pediatric pain, pain
management within the ED is still suboptimal [3–5].
The most commonly used pharmacologic options for
treating acute MSK pain in children are ibuprofen, acet-
aminophen, or opioids [3, 4, 6–8]. Despite this, the current
evidence does not allow physicians or researchers to de-
termine an analgesic strategy that offers an effective pain
management strategy for patients with MSK injury.
Primarily, this is because there are limited studies investi-
gating the effectiveness of combination therapy, even
though monotherapy offers inadequate pain management
in around 50% of cases [9–12]. Thus, the Non-Steroidal or
Opioid Analgesia Use for Children with Musculoskeletal
Injuries study (the No OUCH Study) aims to collect evi-
dence on the relative effectiveness of ibuprofen alone
compared to two combination therapies; ibuprofen plus
acetaminophen or hydromorphone.
There has recently been an effort to reduce opioid pre-
scriptions in children [13, 14] due to concern about the
potential harm from opioids and awareness of “the opi-
oid crisis” in North America. Primarily, these concerns
are based on the use of opioids in adults [15], rather
than direct evidence on their safety and effectiveness
profiles in children. Clinicians have become reticent to
prescribe opioids to children and caregivers are increas-
ingly less willing to accept them [5]. Therefore, the No
OUCH study has been designed to understand and re-
spect caregiver/parent preferences on opioid use.
The No OUCH study will utilize a novel preference-
informed complementary trial design to assess the ef-
fectiveness and safety of ibuprofen, ibuprofen plus acet-
aminophen, and ibuprofen plus hydromorphone as a
treatment for MSK injury-related pain in patients pre-
senting to the ED. This design consists of two phase 2,
multi-center, randomized, double blind, placebo-
controlled trials that will be run simultaneously with the
same study team, outcome definitions, and data manage-
ment systems. The study protocol has been submitted
separately [16]. This article outlines the statistical ana-
lysis plan (SAP) for the No OUCH study; it has been
submitted for publication without knowledge of the
study outcomes.
Primary objective
The primary aim of the No OUCH study is to investi-
gate two hypotheses. Firstly, we hypothesize that a com-
bination of oral ibuprofen and oral acetaminophen has a
greater analgesic effect than ibuprofen alone. Addition-
ally, we hypothesize that a combination of oral ibuprofen
and oral hydromorphone will have greater analgesic effi-
cacy than ibuprofen alone or a combination of oral ibu-
profen and oral acetaminophen. To investigate this, we
will enroll a patient population that is aged between 6
and 17 years and presents at the ED with a limb injury
that is less than 24 h old with a self-reported pain score
at least 5 out of 10, using a verbal Numerical Rating
Scale (vNRS) [17, 18].
Methods/design
Design and setting
The No OUCH study will use a preference-informed
complimentary trial design that allows caregivers/parents
to decide whether to enroll their child in a three-arm trial
or two-arm trial. The three-arm trial (Opioid trial) in-
cludes the comparator ibuprofen plus hydromorphone
alongside ibuprofen plus acetaminophen and ibuprofen
alone. The two-arm trial (Non-Opioid) allows caregivers/
parents to avoid the ibuprofen plus hydromorphone com-
parator. These two randomized, double-blind, placebo-
controlled trials will be run simultaneously across six
Canadian tertiary care pediatric EDs. The inclusion/exclu-
sion criteria, study endpoints, and personnel will be identi-
cal across the two trials and we will consider whether a
single treatment effect estimate across the two trials is
appropriate.
Study protocol development and conduct
The No OUCH study was registered on December 7,
2018, at ClinicalTrials.gov (trial registration number
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NCT03767933). The ethics committee at each partici-
pating site approved the study protocol prior to study
implementation. The study is also regulated and moni-
tored by Health Canada and is being conducted accord-
ing to their recommended best practices. Consent will
be obtained from all caregivers/parents and assent from
participating children, where applicable. The No OUCH
study resides within the KidsCAN-PERC iPCT network
[19], a Canadian trials network with centralized infra-
structure for data management and trial oversight.
Within this network, an independent data and safety
monitoring board has been recruited to monitor the
study processes with a focus on the safety of the
interventions.
Randomization and data collection
Eligible patients will be approached for recruitment
shortly after triage assessment, before analgesic medica-
tions might be offered by the triage nurse. Caregivers/
parents will decide the trial in which they would like to
participate. The Non-Opioid trial randomizes patients in
a 1:1 ratio to either:
(i) Ibuprofen plus acetaminophen placebo OR
(ii) Ibuprofen in combination with acetaminophen.
The Opioid trial randomizes patients in a 1:1:1 ratio to
either:
(i) Ibuprofen plus 2 placebos OR
(ii) Ibuprofen with acetaminophen plus oral
hydromorphone placebo OR
(iii) Ibuprofen with oral hydromorphone plus
acetaminophen placebo.
Within each trial, patients will be randomized,
stratified by center, using block-randomization with
variable block sizes. The relative recruitment rates
for the two trials will be explored at an interim ana-
lysis (outlined below) and changes to the
randomization/allocation ratio from 1:1 or 1:1:1 may
be considered if there are recruitment issues for ei-
ther of the trials.
The randomization order will be generated using a se-
cure, online, centralized randomization tool housed at
the Data Coordinating Centre (DCC) for the KidsCAN-
PERC iPCT network, which is hosted at the Women and
Children’s Health Research Institute (WCHRI) at the
University of Alberta [20]. All research data collected
from the study participants will be stored in the REDCap
electronic data capture system [21]. The database is
housed by the DCC in a secure data server within the
WCHRI.
Primary outcome
The primary outcome across both the No OUCH
study is the self-reported pain score, measured by a
0–10 vNRS at 60 min after study drug administration.
This vNRS has a minimally clinically important differ-




The No OUCH study will include seven secondary effi-
cacy outcomes. Firstly, we will record which children
achieve two alternative definitions of effective analgesia, a
vNRS pain score of less than 3 out of 10, based on the
WHO definition of mild pain [24], and a pain reduction of
at least 2, known as “Patient Satisfaction with Analgesia”
[22], at 60min following the administration of the study
drug. We will also investigate the difference in pain scores
between the treatment arms in the two trials at 30, 60,
and 120min after the treatment administration, as well as
at the time of the medical examination and at X-ray. We
will also investigate whether children required rescue an-
algesia in the 60min following the administration of the
study medication. We will explore the length of stay for
patients in the ED and the length of time to effective anal-
gesia (a vNRS pain score of less than 3). Finally, we will
record the children’s self-reported pain intensity using a
visual analog scale and the Face Pain Scale-Revised (FPS-
R) at all study times [25].
Safety outcomes
The principal safety outcome will be the incidence of
any adverse events related to study drug administration.
Additionally, we will record whether a participant expe-
riences a serious adverse event during the study period
and what types of adverse events they experienced. Fi-
nally, we will record the Ramsay Sedation Score (RSS)
[26] for children in the study. The RSS will be dichoto-
mised and any patient with a score between 1 and 3 will
be deemed “over-sedated” as over-sedation is a potential
risk with any opioid administration. To investigate
whether appropriate pain management leads to issues in
diagnosis, we will investigate the proportion of missed
fractures or dislocations, as reported on follow-up
survey.
Outcomes related to trial selection
The structure of the No OUCH study allows us to
investigate the reasons for selecting the Opioid or Non-
Opioid trial. We will determine the reasons that care-
givers/parents selected the Opioid or Non-Opioid trial,
and their self-reported satisfaction with the pain relief
and comfort at home using a 5-point Likert scale (c.f.
supplementary material). Finally, at ED discharge, we
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will record the analgesic that the physician would have
preferred to give the patient, if the patient were not en-
rolled in the study.
Sample size calculation
The No OUCH study comprises two concurrent trials
with a sample size calculation undertaken separately for
each trial. The sample size for the Opioid Trial is 105
patients per arm or 315 in total. For the Non-Opioid
Trial, the sample size is 85 patients per arm or 170 in
total. Thus, the total recruitment for the No OUCH
study will be a minimum of 485 patients. To account for
missing data for the primary outcome due to early with-
drawal, the study will over-recruit by approximately
10%, for a target recruitment of 540 patients. This sam-
ple size was calculated assuming a two-sided level of
0.05, a power of 0.95, a minimally clinically important
difference of 1.5 on the vNRS and an estimate of the
standard deviation of the difference of 2.7 [22]. We used
a Bonferroni correction to adjust for the three treatment
comparisons in the Opioid trial.
Based on prior survey data, we are not expecting the
two No OUCH trials to complete recruitment at the
same time. Thus, we aim to keep recruitment open for
both trials until both trials reach the required number of
participants. This could require over-recruitment in one
of the two trials and therefore the total recruitment for
the No OUCH study could exceed 540. This over-
recruitment is required to ensure that the caregiver/par-
ent preference aspect of the No OUCH study is
respected throughout. To avoid significant over-
recruitment, we will monitor the recruitment rate of the
two trials. If we face significant over-recruitment for the
Non-Opioid trial, then the study team, in consultation
with the Data Safety Monitoring Board (DSMB), will
consider randomizing a larger proportion of patients to
the hydromorphone plus ibuprofen arm within the Opi-
oid trial to ensure 105 patients are recruited for this
comparator. If the relative recruitment rate to the two
trials is very highly skewed, we will consider stopping
the No OUCH study when the first, rather than the sec-
ond, trial completes recruitment and adjusting our hy-
potheses accordingly.
Interim analyses and stopping guidance
A DSMB with six participants has been created for the
No OUCH study to protect patients and advise the study
team. Biannually, the DSMB will be provided with a
summary and list of the protocol deviations and adverse
events across all trial participants. The DSMB can also
request a summary broken down by treatment group
and trial, alongside the associated p values. The DSMB
will have sole control over whether to stop one or both
the No OUCH trials for safety reasons. The No OUCH
study will not consider early stopping for efficacy or fu-
tility, and thus, no interim analysis is planned for the
outcome measures. No statistical adjustments are made
for interim analyses of the efficacy outcome data.
There will be an initial interim analysis of the relative re-
cruitment rate into the Opioid and Non-Opioid trials to
ensure timely completion of both trials. This interim ana-
lysis of the recruitment rate will take place after 100
patients have been enrolled across the No OUCH study.
Depending on the relative recruitment rates across the
two trials at this interim analysis, we will either continue
to monitor the recruitment rate, change the
randomization ratio in one of the trials, or stop the No
OUCH study once one trial is completed. Any change in
the sample size or randomization ratio will be carefully




Analyses will be performed according to the intention-
to-treat principle. For all relevant parameters, 95% confi-
dence intervals will be presented. Broadly, if an outcome
is subjected to formal statistical testing, we will declare
significance at the 5% level and use a Bonferroni-Holm
correction to adjust the analysis for multiple compari-
sons when required. When descriptive statistics are used,
we will present means, standard deviations, medians,
and interquartile ranges for continuous variables and
summarize discrete variables with frequency distribu-
tions. All analyses will be performed in either SAS [27]
or R [28]. As the endpoints for the two trials are the
same, our primary analysis will consider whether a joint
analysis across the two trials is valid, both from a clinical
and statistical perspective. Thus, the statistician involved
in analyzing the trial data will not be blinded to the
combination of ibuprofen with hydromorphone within
the Opioid trial. However, the statistician will remain
blinded to the other two arms throughout the analysis.
Timing of outcomes and analysis
The majority of the outcomes for the No OUCH study
will be collected while the patient is in the ED for their
enrolment visit. Outcomes related to patient response
and caregiver/parent satisfaction with the intervention
will be collected over the phone or by email. These out-
comes will be collected within 1–3 days of discharge
from the ED and again at 1–2 weeks post-discharge. The
final analysis for the No OUCH study will be undertaken
once every patient has reached 2 weeks after enrollment
and the database has been cleaned and locked. The ana-
lysis will be performed by a statistician who did not as-
sess the trial outcomes.
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Handling of missing data
As the primary endpoint is assessed in the ED within
2 h of treatment allocation, we anticipate minimal miss-
ing data for the primary analysis. The study team will
endeavor to collect the relevant data for all outcomes
and therefore avoid missing data in the secondary or ex-
ploratory outcomes. Multiple imputation will be used to
impute any missing data, including outcomes as re-
quired, in the cleaned and locked dataset [29].
Patient flow
We will use a CONSORT 2010 flow diagram to provide
details on the patient flow [30]. We will report the num-
ber of patients screened, the number of patients who
met our trial inclusion criteria, and the number of pa-
tients ineligible for the No OUCH study based on the
criteria outlined in the trial protocol [16], for both trials.
The CONSORT diagram will also present how many pa-
tients were lost to follow-up and when they withdrew
from the study. We will include the number and reasons
for withdrawal and/or exclusion from analysis at each
stage. Finally, we will provide descriptive statistics for
the sex, age, eligibility criteria, and consent status of all
screened patients across both trials.
Protocol deviations
Within the No OUCH study, protocol deviations are de-
fined as patients who:
(i) Are randomized but do not receive the allocated
study intervention OR
(ii) Did not meet the inclusion criteria or met one of
the exclusion criteria and are enrolled in the study
OR
(iii)Receive the incorrect dose of the study medication.
A patient is said to have successfully adhered to the
treatment if they complete the one-time administration
of the allocated study drugs. As such, we are expecting
high levels of adherence.
We will classify all protocol deviations before unblind-
ing the treatment options. The raw number and the per-
centage of patients with protocol deviations and non-
adherence will be summarized by treatment group. We
will also include details of which type of protocol devi-
ation was experienced. Percentages will be calculated
using the number of patients in the intention to treat
dataset. We will not use formal statistical testing to in-
vestigate protocol deviations.
Baseline characteristics
For both trials, we will present the age, sex, injury type, injury
location, and vNRS score at time of recruitment for both tri-
als and all treatment options, including non-pharmacological
strategies such as a splint. These characteristics will be pre-
sented using appropriate descriptive statistics.
Analysis for the primary endpoint
The primary effectiveness analysis will compare the
vNRS score at 60 min after study drug administration
using linear mixed models to estimate the treatment effect
while adjusting for the vNRS score at baseline and a site-
specific random effect for each of the six participating
sites. As the two No OUCH trials have the same primary
endpoint and inclusion/exclusion criteria, we will consider
whether it is appropriate to estimate a single pooled treat-
ment effect across the two trials. We will only estimate a
single treatment effect, if there is neither clinical nor stat-
istical evidence that this should not be undertaken. To de-
termine clinical rationale for a single pooled treatment
effect, we will evaluate whether the baseline clinical char-
acteristics across the two trials (including pain scores at
baseline) indicate a difference between the two participant
populations. This will be assessed before undertaking ana-
lysis for the primary outcome and will be based on clinical
judgment defined using consensus among experts. The
supplementary material outlines the method we will use
to extract the clinical judgment.
If we determine that there is no clinical evidence
of a difference across the two patient populations,
we will then use a likelihood ratio test to determine
whether there is statistical evidence of a difference
in the treatment effect across the two trials. To per-
form this test, we will fit two nested linear mixed
models for self-reported vNRS pain scores at 60 min,
adjusting for vNRS pain score at baseline and a site-
specific effect. The full model will include a treat-
ment by trial interaction term while the reduced
model will assume a constant treatment effect across
the two trials.
If the likelihood ratio test suggests a superior fit for the
full model at the 5% level, then data from the two trials
will be analyzed separately. In this setting, two linear
mixed models will be used to estimate a trial-specific
treatment effect. These two models will both adjust separ-
ately for baseline vNRS score and site. If the full model
does not provide a statistically superior fit at the 5% level,
then the reduced model will be used to analyze the data
and obtain single treatment effects for ibuprofen in com-
bination with acetaminophen or hydromorphone. The
family-wise error rate will be controlled when declaring
significance for the primary endpoints, irrespective of
whether a pooled a treatment effect is estimated or not.
Analysis for secondary endpoints
If the analysis for the primary outcome provides a single
pooled treatment effect, the analysis for the secondary
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outcomes will be pooled. Otherwise, we will analyze the
trials separately for the secondary outcomes.
Efficacy outcomes
We will compare the proportion of children with a self-
reported vNRS pain score of less than 3 out of 10 at 60
min (success) across treatment groups using a logistic
mixed model, adjusted for site and baseline pain. We
will also use a logistic mixed model to compare the pro-
portion of children who require a rescue analgesic by 60
min, considered as a failure for the analgesic agent,
across the different treatments. For both these outcomes,
we will report the odds ratio and adjust for multiple
comparisons. All other secondary outcomes for effective-
ness will be summarized within each treatment group
using the appropriate descriptive statistics.
Safety outcomes
We will compare the proportion of children with adverse
events related to study drug administration using a logistic
mixed model, adjusted for site. This analysis will not ad-
just for baseline pain. All other safety outcomes will be
summarized using appropriate descriptive statistics.
Trial selection outcomes
All outcomes relating the caregiver/patient trial preference
will be summarized using appropriate descriptive statis-
tics. They will also be further explored in a qualitative sub-
study to illuminate the reasons for avoiding opioids.
Subgroup analyses
We will perform two pre-planned exploratory subgroup
analyses comparing the self-reported vNRS pain score at
60 min by age group, under and over or equal to 12
years, and by type of injury, fracture or soft tissue injury.
These analyses will be undertaken using linear mixed
models with an interaction term between treatment and
subgroup. These analyses will be performed within each
trial separately or pooled across the two trials depending
on the analysis for the primary endpoint.
Sensitivity analyses
If the two trial populations are analyzed together as the
primary analysis, we will analyze the two trials separately
as a sensitivity analysis. We will undertake the primary
analysis considering self-reported vNRS pain score as an
ordinal categorical variable, rather than a continuous
variable. Finally, we will undertake an exploratory ana-
lysis from a Bayesian perspective for the primary out-
come and all secondary outcomes that are subject to
frequentist testing. This analysis will use minimally in-
formative and informative priors. The posterior distribu-
tions for the parameters will be summarized using
posterior means and 95% posterior credible intervals.
Trial status
The No OUCH study was registered on December 7,
2018, at ClinicalTrials.gov and started recruitment at the
Stollery Children’s Hospital on May 13, 2019. Recruit-
ment is currently underway and is expected to complete
around summer 2021. Before the data are analyzed, the
database will be cleaned and checked for completeness,
blinded to treatment allocation. The database will be
locked and the analysis will be undertaken using the
methods specified in this SAP.
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.
1186/s13063-020-04503-y.
Additional file 1. Pooling Guidelines
Additional file 2. 5-Point Likert Scale
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